Altria Group is accelerating investment in smoke-free alternatives such as oral nicotine pouches while leaning on the pricing power of its legacy cigarette brands to fund the transition. The company recently highlighted ongoing pressures in the traditional cigarette business and increased regulatory scrutiny. Altria has continued share repurchases and affirmed its US$1.06 quarterly dividend, signaling it is still directing substantial cash to shareholders even as it invests in reduced-risk products. The investment narrative projects $20.3 billion in revenue and $9.5 billion in earnings by 2029, though some analysts are more pessimistic, assuming roughly flat revenue near US$20.7 billion and earnings of about US$9.5 billion by 2029 if illicit e-vapor growth and tighter FDA decisions reshape smoke-free plans. The biggest risk remains regulatory decisions and enforcement, particularly around smoke-free products and illicit e-vapor.
Altria GroupArticle discusses Altria's share repurchases and dividend, but also highlights regulatory risks and uncertain revenue projections.